Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel
Madrigal Pharmaceuticals (NASDAQ:MDGL) has appointed Shannon Kelley as General Counsel, effective August 5, 2024. Kelley, who joined Madrigal in 2024 as Chief Compliance Officer, brings over 20 years of healthcare legal and compliance experience. Previously, she held senior roles at Sanofi and Boston Scientific , and worked in enforcement roles with the U.S. Federal Government.
CEO Bill Sibold praised Kelley's leadership and expertise, highlighting her instrumental role in guiding the company through rapid growth. Kelley expressed enthusiasm about Madrigal's opportunity to deliver groundbreaking therapy for nonalcoholic steatohepatitis (NASH), the leading cause of liver transplantation in women in the U.S. She aims to be a strategic partner in building an industry-leading company with a strong culture of ethics and integrity.
Madrigal Pharmaceuticals (NASDAQ:MDGL) ha nominato Shannon Kelley come Consigliere Generale, con effetto dal 5 agosto 2024. Kelley, che è entrata in Madrigal nel 2024 come Chief Compliance Officer, porta con sé oltre 20 anni di esperienza legale e di conformità nel settore sanitario. In precedenza, ha ricoperto ruoli di alto livello presso Sanofi e Boston Scientific, e ha lavorato in ruoli di enforcement con il governo federale degli Stati Uniti.
Il CEO Bill Sibold ha elogiato la leadership e la competenza di Kelley, sottolineando il suo ruolo fondamentale nel guidare l'azienda attraverso una rapida crescita. Kelley ha espresso entusiasmo per l'opportunità di Madrigal di fornire terapie innovative per la steatoepatite non alcolica (NASH), la principale causa di trapianti di fegato tra le donne negli Stati Uniti. Si propone di essere un partner strategico nella costruzione di un'azienda leader del settore con una forte cultura di etica e integrità.
Madrigal Pharmaceuticals (NASDAQ:MDGL) ha nombrado a Shannon Kelley como Consejera General, con efecto a partir del 5 de agosto de 2024. Kelley, quien se unió a Madrigal en 2024 como Directora de Cumplimiento, aporta más de 20 años de experiencia legal y de cumplimiento en el sector de la salud. Anteriormente, ocupó roles importantes en Sanofi y Boston Scientific, y trabajó en funciones de cumplimiento con el gobierno federal de EE. UU.
El CEO Bill Sibold elogió el liderazgo y la experiencia de Kelley, destacando su papel fundamental en guiar a la empresa a través de un rápido crecimiento. Kelley expresó entusiasmo por la oportunidad de Madrigal de ofrecer terapias innovadoras para la esteatohepatitis no alcohólica (NASH), la principal causa de trasplante de hígado en mujeres en EE. UU. Busca ser una socia estratégica en la construcción de una empresa líder en la industria con una sólida cultura de ética e integridad.
마드리갈 제약 (NASDAQ:MDGL)는 샤넌 켈리를 2024년 8월 5일부터 법률 고문으로 임명했습니다. 켈리는 2024년에 마드리갈에 합류하기 전, 20년 이상의 의료 분야 법률 및 준수 경험을 보유하고 있습니다. 이전에는 사노피와 봇손 사이언티픽에서 고위직을 역임했으며, 미국 연방 정부에서 법 집행 역할로 일한 바 있습니다.
CEO 빌 시볼드 는 켈리의 리더십과 전문성을 높이 평가하며, 그녀가 회사의 급속한 성장을 이끄는 데 중요한 역할을 했다고 강조했습니다. 켈리는 마드리갈이 비알콜성 지방간염(NASH)을 위해 groundbreaking therapy를 제공할 수 있는 기회에 대해 열정을 표현했습니다. 그녀는 윤리와 진실성을 중시하는 강력한 기업 문화를 가진 업계 선두 주자로 자리잡기 위한 전략적 파트너가 되는 것을 목표로 하고 있습니다.
Madrigal Pharmaceuticals (NASDAQ:MDGL) a nommé Shannon Kelley au poste de Conseillère Générale, à compter du 5 août 2024. Kelley, qui a rejoint Madrigal en 2024 en tant que Directrice de la Conformité, apporte plus de 20 ans d'expérience juridique et de conformité dans le secteur de la santé. Auparavant, elle a occupé des postes de direction chez Sanofi et Boston Scientific, et a travaillé dans des rôles d'exécution au sein du gouvernement fédéral américain.
Le PDG Bill Sibold a salué le leadership et l'expertise de Kelley, mettant en avant son rôle essentiel dans la direction de l'entreprise durant sa croissance rapide. Kelley a exprimé son enthousiasme quant à l'opportunité pour Madrigal de fournir des thérapies novatrices pour la stéatohépatite non alcoolique (NASH), principale cause des transplantations de foie chez les femmes aux États-Unis. Elle vise à être un partenaire stratégique pour bâtir une entreprise leader dans l'industrie avec une forte culture d'éthique et d'intégrité.
Madrigal Pharmaceuticals (NASDAQ:MDGL) hat Shannon Kelley mit Wirkung zum 5. August 2024 zur General Counsel ernannt. Kelley, die 2024 als Chief Compliance Officer zu Madrigal kam, bringt über 20 Jahre Erfahrung im Bereich Recht und Compliance im Gesundheitswesen mit. Zuvor hatte sie leitende Positionen bei Sanofi und Boston Scientific inne und arbeitete in der Durchsetzungsbehörde der US-Bundesregierung.
Der CEO Bill Sibold lobte Kelleys Führung und Fachwissen und hob ihre entscheidende Rolle bei der Führung des Unternehmens durch schnelles Wachstum hervor. Kelley äußerte ihre Begeisterung für die Opportunity von Madrigal, bahnbrechende Therapien für nichtalkoholische Steatohepatitis (NASH) anzubieten, die die Hauptursache für Lebertransplantationen bei Frauen in den USA ist. Sie beabsichtigt, eine strategische Partnerin beim Aufbau eines führenden Unternehmens der Branche mit einer starken Kultur von Ethik und Integrität zu sein.
- Appointment of experienced legal professional Shannon Kelley as General Counsel
- Kelley's extensive 20+ years of healthcare legal and compliance experience
- Potential for strengthened leadership and strategic guidance in a period of rapid growth
- None.
CONSHOHOCKEN, Pa., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced the appointment of Shannon Kelley as General Counsel, effective August 5, 2024.
Bill Sibold, Chief Executive Officer of Madrigal, stated, “Shannon is an outstanding leader who brings a wealth of expertise to her new role as General Counsel. She joined the Madrigal team in 2024 as Chief Compliance Officer and played an instrumental role guiding the company through a period of rapid growth. I feel privileged to be working with Shannon and the other members of our leadership team as we build the foundation for Madrigal’s future.”
Ms. Kelley has more than 20 years of diverse healthcare experience as a legal and compliance professional. She joined Madrigal from Sanofi, where she served in roles of increasing responsibility. She was most recently Chief Compliance Officer, North America and Global Specialty Care, responsible for compliance across all therapeutic areas. Prior to Sanofi, Ms. Kelley was Global Compliance and Commercial Legal Counsel for Boston Scientific Corporation. Earlier in her career, she spent ten years in enforcement roles with the U.S. Federal Government. Ms. Kelley was a Trial Attorney for the Department of Justice in Washington, D.C. and an Assistant United States Attorney and Deputy Chief of Litigation for the U.S. Attorney’s Office for the District of Massachusetts focused on healthcare matters. Ms. Kelley earned her J.D. from American University Law School and holds a B.S. degree from Georgetown University in Foreign Service.
Ms. Kelley stated, “At Madrigal, we have a unique opportunity to deliver a groundbreaking therapy to patients living with NASH, the leading cause of liver transplantation in women in the U.S. and the second leading cause for all liver transplantation. Our goal is to build a great company that will be an industry leader for years to come, and I look forward to being a strategic partner to the leadership team and continuing to build a strong culture of ethics and integrity.”
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of NASH. For more information, visit www.madrigalpharma.com.
Investor Contact
Tina Ventura, IR@madrigalpharma.com
Media Contact
Christopher Frates, media@madrigalpharma.com
FAQ
Who is Shannon Kelley and what is her new role at Madrigal Pharmaceuticals (MDGL)?
What is Madrigal Pharmaceuticals (MDGL) focused on developing?
What is Shannon Kelley's professional background before joining Madrigal Pharmaceuticals (MDGL)?
When did Shannon Kelley join Madrigal Pharmaceuticals (MDGL) and in what capacity?
